Diabetes, Cardiology & Novel therapeutic Approaches: Science, Outcomes and Practice
Diabetes, Cardiology & Novel Therapeutic Approaches: Science, Outcomes and Practice
EBAC accredited symposium held at WCC 2018Agenda - Dec. 6, 2018 - WCC, Dubai, UAE
If you are attending WCC congress 2018 in Dubai, UAE, you are cordially invited to attend this symposium
Thursday, December 6, 2018: 13:00 – 14:00 hrs, room Sheikh Rashid A
- Understand the relation between T2DM & Cardiovascular Disease
- Identify the needs for novel approaches targeting T2DM in cardiovascular prevention
- Explore results from recent cardiovascular outcome trials (CVOT) in T2DM
- Discuss potential mechanisms and multifactorial effects of GLP-1 receptor agonists contributing to cardiovascular benefits
- Review results from recent GLP1 RA outcomes trials, such as LEADER on CV and microvascular outcomes.
- Discuss practical implications from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.
- Introduction, Wael Al Mahmeed, MD, Abu Dhabi, UAE
- Diabetes & CVD: Time for a multifactorial approach, John E Deanfield, MD, London, United Kingdom
- Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control, Lina Badimon, Barcelona, Spain
- Translating GLP-1 trial outcomes to cardiology practice: Which patients will benefit?, Neil Poulter, MD, London, United Kingdom
- Panel discussion, Wael Al Mahmeed, MD - John E Deanfield, MD
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
Supported by an unrestricted educational grant received from Novo Nordisk